77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

• DOI: 10.1016/j.iotech.2022.100181
• Publication Date: 2022-12-09T10:08:20Z
• Authors: Y. Cheng; B. Liu; L. Wu; T. Zhang; K. Wang; L. Miao; J. Wu; H. Wang; J. Fang; X. Li; W. Zhang; Y. Hu; X. Mei; Y. Song; C. Wu; J. Zhu; Y. Xin; Y. Chen; G. Han; J. Ye
• Keywords: Tolerability